Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors

Inclusion Criteria: * Written, signed, IRB-approved informed consent form. * Pathologic (histologic or cytologic) confirmation of metastatic or locally advanced solid tumor. * Patients must have a pathologically documented, definitively diagnosed, advanced solid tumor that is refractory to standard treatment, for which no standard therapy is available or the patient refuses standard therapy. * One or more tumors measurable by RECIST criteria. * Karnofsky performance status ≥ 70%. * Ejection fraction ≥ 50%, determined by echocardiogram. * Life expectancy at least 3 months. * Age ≥ 18 years. * Acceptable organ function; normal hepatic, renal and hematopoietic function. * Negative serum or urine pregnancy test result in women of childbearing potential. Exclusion Criteria: * Known brain metastasis. * New York Heart Association Class III or IV cardiac disease, myocardial infarction within 6 months of enrollment, or cardiac arrhythmia requiring medical therapy. * Active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy. * Patients with uncontrolled diabetes (requiring medication change within 30 days of screening), or requiring insulin therapy. * Heparin therapy. * Known infection with HIV, hepatitis B, or hepatitis C. * Known allergy to hyaluronidase. * Women currently breast feeding.